Topotecan

Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy.
Do not take if: HYCAMTIN is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan.
Reactions have included anaphylactoid reactions.

What it is used for

HYCAMTIN ® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

Myelosuppression
Diarrhea
Interstitial Lung Disease (ILD)

Who should not take it

HYCAMTIN is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. Reactions have included anaphylactoid reactions.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Topotecan; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/topotecan
APA 7th: sofidex. (2026, August 3). Topotecan. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/topotecan
AMA 11th: Topotecan. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/topotecan

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.